Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AngioDynamics Gains AngioVac Clot Remover In $55 Mil. Vortex Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Deal strengthens peripheral vascular product offerings with the addition of 510(k)-cleared blood clot removal system, which AngioDynamics expects will generate $50 million in annual sales in five years.

You may also be interested in...



Supreme Court Won’t Hear Biolitec-AngioDynamics Case

The high court declined to hear arguments in the dispute between Biolitec and AngioDynamics on Nov. 30, leaving Biolitec responsible for damages and contempt of court penalties that could be as high as $160 million.

People In Brief

Infraredx appoints new CFO. AngioDynamics names former Navilyst Medical exec to senior VP spot. More people briefs.

AngioDynamics Doubles Vascular Access Biz With Navilyst Acquisition

Deal worth $372 million makes AngioDynamics the clear number-two competitor in the global vascular access market, second only to Bard.

Topics

Related Companies

UsernamePublicRestriction

Register

MT031634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel